{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Wharton Jelly Mesenchymal stem cells",
            "NStudiesAvail": 430108,
            "NStudiesFound": 40,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 40,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Abdallah Awidi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 15, 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Patients will be assessed for any relevant adverse event resulting from the intracavernous injection of the Wharton jelly mesenchymal stem cells."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]"
                        ],
                        "NCTId": [
                              "NCT02945449"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Abdalla Awidi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number, frequency and severity of injection associated adverse events.\nThe nephrologist will record any adverse event at each follow up visit in addition to evaluation of the overall condition of the patient."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]"
                        ],
                        "NCTId": [
                              "NCT03288571"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Abdalla Awidi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 13, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Patients will be evaluated for the efficacy of the intracavernous injection of Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography in which peak systolic velocity of the cavernosal arteries will be measured.",
                              "The efficacy of the intracavernous injection of Wharton Jelly will be evaluated by scoring the SHIM/IIEF/EHS questionnaires."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by Penile Doppler ultrasonography.",
                              "Assessment of the efficacy of injecting Wharton Jelly derived Mesenchymal Stem Cells by SHIM/IIEF/EHS questionnaires"
                        ],
                        "NCTId": [
                              "NCT03751735"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Treatment adverse events are defined by any adverse event leading to hospitalization, organ failure or death"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]"
                        ],
                        "NCTId": [
                              "NCT03299413"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 30, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Improvement of clinical symptoms including duration of fever, respiratory destress, pneumonia, cough, sneezing, diarrhea.",
                              "Side effects measured by Chest Readiograph",
                              "Results of Real-Time Polymerase Chain Reaction of Viral RNA, Turing negative"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Clinical outcome",
                              "CT Scan",
                              "RT-PCR results"
                        ],
                        "NCTId": [
                              "NCT04313322"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 8, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "(S)AESI are defined as:\n\nMeningitis and encephalitis.\nToxic encephalopathy.\nHigh fever >39\u2070C.\nEpileptic seizures that are not connected to conditions above (meningitis, encephalitis, toxic encephalopathy, high fever)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The number of (S)AESI [(Serious) Adverse Event of Special Interest]"
                        ],
                        "NCTId": [
                              "NCT04651855"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Joan Vidal, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 25, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Adverse events"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of treatment-emergent adverse events"
                        ],
                        "NCTId": [
                              "NCT03003364"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Abdallah Awidi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "patients will be monitored for any adverse events resulting from the intraarticular injection of WJMSC"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Evaluation of the safety and tolerability of the intra articular injection"
                        ],
                        "NCTId": [
                              "NCT02963727"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Joseph McGuirk, DO"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "August 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "TRSAE is defined as a serious adverse event (SAE) that has a \"probable\" or \"definite\" relation to the MSCTC-0010 infusion. This study will use the descriptions and grading scales from Common Terminology Criteria for Adverse Events version 4.03 (CTCAE v4.03) for hematologic and non-hematologic toxicities."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "proportion of participants who have a TRSAE after infusion of MSCTC 0010"
                        ],
                        "NCTId": [
                              "NCT03158896"
                        ]
                  },
                  {
                        "Rank": 10,
                        "OverallOfficialName": [
                              "Antoine KIMMOUN, MD, PhD",
                              "S\u00e9bastien GIBOT, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 14, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoint is the percentage of patients with a PaO2/FiO2 ratio > 200 at D10 of treatment with MSC-GW or placebo."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "PaO2 / FiO2 ratio"
                        ],
                        "NCTId": [
                              "NCT04625738"
                        ]
                  },
                  {
                        "Rank": 11,
                        "OverallOfficialName": [
                              "Armin Attar, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "November 1, 2025"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The incidence of heart failure during the follow-up period."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Incidence of Heart Failure"
                        ],
                        "NCTId": [
                              "NCT05043610"
                        ]
                  },
                  {
                        "Rank": 12,
                        "OverallOfficialName": [
                              "Umut Arslan, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 30, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The visual acuity scores obtained from the baseline testing and the final examination were analyzed and compared statistically to determine effectiveness."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "ETDRS visual acuity"
                        ],
                        "NCTId": [
                              "NCT04224207"
                        ]
                  },
                  {
                        "Rank": 13,
                        "OverallOfficialName": [
                              "Alfredo Hernandez-Ruiz, MSc"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Evaluation of efficacy of WJ-MSC defined by mortality at 28 days of application."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Intergroup mortality difference with treatment"
                        ],
                        "NCTId": [
                              "NCT04390152"
                        ]
                  },
                  {
                        "Rank": 14,
                        "OverallOfficialName": [
                              "Kuddusi ERKILI\u00c7, Professor"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 1, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Visual acuity change with LogMar Chart",
                              "Mean deviation values of automatic visual field testing"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Evaluation of best corrected visual acuity change",
                              "Evaluation of visual field change"
                        ],
                        "NCTId": [
                              "NCT05413148"
                        ]
                  },
                  {
                        "Rank": 15,
                        "OverallOfficialName": [
                              "Lian Ru Gao, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2012"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary endpoints were differences between the two treatments and from baseline to 4 months in quantitative myocardial metabolic and perfusion images, as measured by 18F-FDG positron emission tomography and 99 mTctetrofosmine single-photon imaging. Left ventricular ejection fraction is measured by 16-segment 2-D echocardiography."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Quantify myocardium metabolic and perfusion measured by F-18-fluorodeoxyglucose (F-18-FDG) postremission tomography (PET) and 99 mTctetrofosmine single-photon (SPET), as well as global left ventricular ejection fraction measured by echocardiography."
                        ],
                        "NCTId": [
                              "NCT01291329"
                        ]
                  },
                  {
                        "Rank": 16,
                        "OverallOfficialName": [
                              "Marek Postula, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change in HOOS score. HOOS consists of 5 subscales: pain, other symptoms, function in activities of daily living (ADL), and function in sport and recreation (Sport/Rec), and hip-related quality of life (QOL). In total, 40 items: 10 items for pain, 5 items for other symptoms (3 for symptoms and 2 for stiff- ness), 17 items for function in ADL, 4 items for function in Sport/Rec, and 4 items for hip-related QOL. Standardized answer options are given (5 Likert boxes) and each question is scored from 0 to 4. Scores are summarized for each subscale and trans- formed to a 0-100 scale (0 indicating extreme problems and 100 indicating no problems).",
                              "Change in Harris Hip Score (HHS) The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stair use, using public transportation, sitting, and managing shoes and socks) and gait (limp, support needed, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).",
                              "Change in KOOS score\n\nIt holds 42 items in 5 separately scored subscales; Pain, other Symptoms, Function in daily living (ADL), Function in Sport and Recreation (Sport/Rec), and knee-related Quality of Life (QOL)\n\nThe five patient-relevant subscales of KOOS are scored separately: Pain (nine items); Symptoms (seven items); ADL Function (17 items); Sport and Recreation Function (five items); Quality of Life (four items). A Likert scale is used and all items have five possible answer options scored from 0 (No Problems) to 4 (Extreme Problems). Scores are transformed to a 0-100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopaedic assessment scales and generic measures.",
                              "Change in modified Harris Hip Score (HHS) The domains covered are pain, function, absence of deformity, and range of motion. The pain domain measures pain severity and its effect on activities and need for pain medication. The function domain consists of daily activities (stair use, using public transportation, sitting, and managing shoes and socks) and gait (limp, support needed, and walking distance). Deformity takes into account hip flexion, adduction, internal rotation, and extremity length discrepancy. Range of motion measures hip flexion, abduction, external and internal rotation, and adduction. There are 10 items. The score has a maximum of 100 points (best possible outcome) covering pain (1 item, 0-44 points), function (7 items, 0-47 points), absence of deformity (1 item, 4 points), and range of motion (2 items, 5 points).",
                              "Change in IKDC Questionnaire score\n\nThe questionnaire looks at 3 categories: symptoms, sports activity, and knee function. The symptoms subscale helps to evaluate things such as pain, stiffness, swelling and giving-way of the knee.\n\nScores are obtained by summing the individual items, then transforming the crude total to a scaled number that ranges from 0 to 100. This final number is interpreted as a measure of function with higher scores representing higher levels of function\n\nThe transformed score is interpreted as a measure of function such that higher scores represent higher levels of function and lower levels of symptoms. A score of 100 is interpreted to mean no limitation with activities of daily living or sports activities and the absence of symptoms.",
                              "Change in WOMAC score. WOMAC score is used to assess patients with osteoarthritis of the hip or knee using 24 parameters in 5 categories.\n\n1 Pain 2.Stiffness 3.Physical function 4.Social function 5. Emotional function\n\nScoring and Interpretation\n\nResponse : points none - 0 slight 1 moderate 2 severe 3 extreme 4\n\nscore = = summary (points for relevant items) average score = = (total score) / (number of items) Interpretation: minimum total score: 0 maximum total score: 96 minimum pain subscore: 0 maximum pain subscore: 20 minimum stiffness subscore: 0 maximum stiffness subscore: 8 minimum physical function subscore: 0 maximum physical function subscore: 6",
                              "Change in DASH score\n\nThe Disabilities of the Arm, Shoulder and Hand (DASH) outcome measure is a 30-item. The items enquire about the degree of difficulty in performing different physical activities because of arm, shoulder and hand problems (21 items), the severity of each of the symptoms of pain, activity-related pain, tingling, weakness and stiffness (five items) and the impact of the problem on social functioning, work, sleep and self-image (four items).\n\nThe scores are then used to calculate a scale score ranging from 0 (no disability) to 100 (most severe disability\n\nA minimum score is 30; a maximum is 150. The range of the scores, therefore-from 30 to 150-equals 120. The raw score is then transformed to a zero-to-100 scale with zero reflecting no disability (good function) and 100 reflecting maximum disability.",
                              "Change in CMS. The Constant-Murley score (CMS) is a 100-points scale composed of a number of individual parameters. These parameters define the level of pain and the ability to carry out the normal daily activities of the patient\n\nThe test is divided into four subscales: pain (15 points), activities of daily living (20 points), strength (25 points) and range of motion: forward elevation, external rotation, abduction and internal rotation of the shoulder (40 points). The higher the score, the higher the quality of the function",
                              "Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles. Visual analogue scales (VAS) are psychometric measuring instruments designed to document the characteristics of disease-related symptom severity in individual patients and use this to achieve a rapid (statistically measurable and reproducible) classification of symptom severity and disease control The VAS is a commonly used tool in health outcome studies, when using it to assess importance of certain action or intervention, how we can interpret the results, on 1 to 10 line (where 1; the least and the 10; the highest),"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "HIP DISABILITY AND OSTEOARTHRITIS OUTCOME SCORE (HOOS)",
                              "Harris Hip Score",
                              "Knee injury and Osteoarthritis Outcome Score (KOOS)",
                              "modified Harris Hip Score for knee",
                              "The International Knee Documentation Committee (IKDC Questionnaire)",
                              "WOMAC (for hip and knee)",
                              "Disability of Arm, Shoulder and Hand [DASH]",
                              "The Constant-Murley score (CMS)",
                              "Visual Analog Scale (VAS)"
                        ],
                        "NCTId": [
                              "NCT03866330"
                        ]
                  },
                  {
                        "Rank": 17,
                        "OverallOfficialName": [
                              "Lian Ru Gao, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Including death from any cause; a composite of major adverse cardiovascular events of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death and hospitalization for unstable angina that led to urgent coronary revascularization;"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The primary end point was checking incidence of adverse events (AEs) within 12 months,"
                        ],
                        "NCTId": [
                              "NCT04551456"
                        ]
                  },
                  {
                        "Rank": 18,
                        "OverallOfficialName": [
                              "Antoni Bayes-Gen\u00eds, MD, PhD,FESC"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Safety measured with a combined endpoint of serious clinical events (death or rehospitalization due to any cause) and serious adverse reactions related to the investigational treatment."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Rate of death or rehospitalization due to any cause and / or adverse reactions related to the procedure / product under investigation."
                        ],
                        "NCTId": [
                              "NCT03798353"
                        ]
                  },
                  {
                        "Rank": 19,
                        "OverallOfficialName": [
                              "John Londono, MD,PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT04432545"
                        ]
                  },
                  {
                        "Rank": 20,
                        "OverallOfficialName": [
                              "Ning K Zhang, MS"
                        ],
                        "OverallOfficialRole": [
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 1, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "the incidence of adverse events (AEs) within 12 months, including death, nonfatal MI, stroke, hospitalization for worsening heart function, severe arrhythmias, repeated coronary intervention, stent thrombosis, coronary artery microvascular obstruction, immune system disorders, or ectopic tissue formation, was monitored and quantified. Laboratory assays, including biochemical assays, hematologic, tumor and immune indexes and Holter monitoring, were performed at the different follow-up times at 1 months-1 year. The trial will be monitored by a Data and Safety Monitoring Board (DSMB) and the trial will be discontinued in case of safety concerns."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The primary end point was safety in incidence of adverse events (AEs) within 12 months"
                        ],
                        "NCTId": [
                              "NCT02368587"
                        ]
                  },
                  {
                        "Rank": 21,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Not Applicable"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 26, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Participants will perform as many sit-to-stand movements as they can in 30 seconds and then will rate pain",
                              "Participants will perform a supine to upright movement as quickly as they can and then will rate pain",
                              "Participants will ascend and decent 10 stairs as quickly as they can and then will rate pain"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in Western Ontario and McMaster Universities Arthritis Index (WOMAC) over 3 months",
                              "Change in pain during sit-to-stand over 3 months",
                              "Change in pain during supine to upright over 3 months",
                              "Change in pain during ascent/decent stairs over 3 months"
                        ],
                        "NCTId": [
                              "NCT03337243"
                        ]
                  },
                  {
                        "Rank": 22,
                        "OverallOfficialName": [
                              "Wojciech Maksymowicz, MD, Prof."
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2018"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "ALSFRS is ordinal rating scale questionnaire (rating 0-4 for each question, 4 is most functional, 0-48 total) of 12 functional activities. The most functional total score is 48. The First time the ALSFRS questionnaire has been dane after enrolment of the patients and then after 6 months of observation and stem cell injections the ALSFRS has been dane every 2 months up to 1,5 year of follow-up period."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) between patients before and after stem cell transplantation."
                        ],
                        "NCTId": [
                              "NCT02881476"
                        ]
                  },
                  {
                        "Rank": 23,
                        "OverallOfficialName": [
                              "Jesus Perez",
                              "Juan Parcero"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 15, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of patients with changes in percentage of resting Oxygen saturation (%O2)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Oxygen saturation"
                        ],
                        "NCTId": [
                              "NCT04456361"
                        ]
                  },
                  {
                        "Rank": 24,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 30, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Percentage of improvement in left ventricular ejection fraction (LVEF) on transthoracic echocardiography and cardiac magnetic resonance imaging (MRI)",
                              "Percentage of improvement of the final diastolic and systolic volumes on transthoracic echocardiography and cardiac MRI",
                              "Effect on viability, defined as a percentage of wall involvement, and improvement in segment-to-segment contractility measured with MRI",
                              "Incidence of ventricular arrhythmias defined as nonsustained ventricular tachycardia (NSTV) or high- or low-grade ventricular extrasystoles"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Left ventricular ejection fraction (LVEF)",
                              "Final diastolic and systolic volumes",
                              "Left ventricule viability",
                              "Ventricular arrhythmias"
                        ],
                        "NCTId": [
                              "NCT04011059"
                        ]
                  },
                  {
                        "Rank": 25,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Enrolling by invitation"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change in the VAS at 1, 3, 6, 9, and 12 months after the transplantation of Wharton's jelly-derived MSCs (WJ-MSCs), compared to before the transplantation.\n\non a scale of 0 to 10, with 0 meaning no pain and 10 meaning the worst pain you can imagine."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "improvement in Visual Analogue Scale"
                        ],
                        "NCTId": [
                              "NCT05018637"
                        ]
                  },
                  {
                        "Rank": 26,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The visual acuity scores obtained from the T0 and T2 examinations were analyzed and compared using statistical tests to determine effectiveness."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "ETDRS visual acuity:"
                        ],
                        "NCTId": [
                              "NCT04877067"
                        ]
                  },
                  {
                        "Rank": 27,
                        "OverallOfficialName": [
                              "Piotr Musia\u0142ek, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "July 2, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Reduction of infarct size assessed in cardiac MRI during index hospitalization and in 6 month FU between two groups (active vs sham)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Reduction of infarct size"
                        ],
                        "NCTId": [
                              "NCT03404063"
                        ]
                  },
                  {
                        "Rank": 28,
                        "OverallOfficialName": [
                              "Jingbo Wang"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2019"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The overall survival ratio of three groups will be detection after infusion in one year."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "overall survival"
                        ],
                        "NCTId": [
                              "NCT03529136"
                        ]
                  },
                  {
                        "Rank": 29,
                        "OverallOfficialName": [
                              "Antoni Torres, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of patients who died, by treatment group"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "All-cause mortality at day 28"
                        ],
                        "NCTId": [
                              "NCT04390139"
                        ]
                  },
                  {
                        "Rank": 30,
                        "OverallOfficialName": [
                              "Lian Ru Gao, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The main safety endpoints was the first occurrence of a major adverse cardiovascular event (a composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and hospitalization for unstable angina that led to urgent coronary revascularization within 12 months.",
                              "The main feasibility endpoints were defined as the change in LVEF, infarct size as determined by MRI and perfusion defect as assessed by MIBI SPECT from baseline to 6 months.",
                              "The main feasibility endpoints were defined as the change in infarct size",
                              "The main feasibility endpoints were defined as non significant perfusion defect"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Any composite of major adverse cardiovascular events",
                              "Checking patient LVEF",
                              "Checking patient infarct size",
                              "checking patient perfusion defect."
                        ],
                        "NCTId": [
                              "NCT04551443"
                        ]
                  },
                  {
                        "Rank": 31,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "evaluation the best passage of MSC culture by CD49 surface marker"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "evaluation the best passage of MSC culture by CD49 surface marker"
                        ],
                        "NCTId": [
                              "NCT05093725"
                        ]
                  },
                  {
                        "Rank": 32,
                        "OverallOfficialName": [
                              "Omar Aljitawi, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "No"
                        ],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 2016"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Use the Wharton's Jelly matrix as a scaffold, we should be able to remove the cellular components of Wharton's Jelly. This decellularization process will help decrease antigenicity and accordingly avoid allosensitization. Additionally, the matrix should be able to provide a 3 dimensional (3D) environment needed for biologic and geometric recellularization."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Isolation and decellularization of umbilical cord Wharton's jelly matrix"
                        ],
                        "NCTId": [
                              "NCT01166776"
                        ]
                  },
                  {
                        "Rank": 33,
                        "OverallOfficialName": [
                              "Martha L Arango, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "December 31, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Pain will be measured through visual analog scale (VAS).",
                              "Joint functionality will be measured through the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC).",
                              "Quality of life will be measured through the Short Form 36 Health Survey Questionnaire (SF-36).",
                              "The improvement of articular cartilage will be evaluated by nuclear magnetic resonance (NMR)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Decrease in joint pain",
                              "Increased joint functionality",
                              "Improvement in the quality of life",
                              "Imaging improvement of articular cartilage"
                        ],
                        "NCTId": [
                              "NCT04863183"
                        ]
                  },
                  {
                        "Rank": 34,
                        "OverallOfficialName": [
                              "Sukmawati T Tan, Dr. dr.",
                              "Siufui Hendrawan, Dr. dr"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator",
                              "Study Director"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 10, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Assessing ulcer progression macroscopic evaluation of:\n\nThe presence of granulation tissue\nThe size of the ulcer reduced\nEdema decreases\nErythema decreases\n\nResults are expressed as means \u00b1 SD. The normal distribution of the data was assessed using the Shapiro-Wilk test. For multiple comparisons One-Way Analysis of Variance (ANOVA) was used. The significance between two independent groups was determined by independent Student's t-test and the Mann-Whitney test. An unpaired t-test was performed if the data were normally distributed. Otherwise, a Mann-Whitney test was used. Statistical analysis was 2-tailed and values were considered statistically significant at p < 0.05."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Knowing the the success rate of chronic ulcer healing in patients undergoing wound care with conditioned medium"
                        ],
                        "NCTId": [
                              "NCT04134676"
                        ]
                  },
                  {
                        "Rank": 35,
                        "OverallOfficialName": [
                              "Antoine MONSEL, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 26, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "Respiratory efficacy evaluated by the increase in PaO2/FiO2 ratio from baseline to day 7 in the experimental group compared with the placebo group"
                        ],
                        "NCTId": [
                              "NCT04333368"
                        ]
                  },
                  {
                        "Rank": 36,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 15, 2020"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "the (ASIA)/(ISNCSCI) to evaluate any motor or neurological changes, and the spinal cord independence measure (SCIM III) score to evaluate the effect on daily activities .these tests will be repeated every 3 months.\n\nblood samples will be withdrawn from patients as well to detect any biomarkers.",
                              "post MSCs transplantation, patients' spine will be imaged using 3 Tesla MRI and compared to baseline."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "SCI evaluation and patients follow up",
                              "SCI evaluation and MSCs transplantation"
                        ],
                        "NCTId": [
                              "NCT04288934"
                        ]
                  },
                  {
                        "Rank": 37,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [
                              "No"
                        ],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "June 15, 2017"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The expression of miRNAs 136, 494 and 495 in exosomes of peripheral blood and UCMSCs conditioned media"
                        ],
                        "NCTId": [
                              "NCT03562715"
                        ]
                  },
                  {
                        "Rank": 38,
                        "OverallOfficialName": [
                              "Badrul Akmal Hisham, MBBS"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Unknown status"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "September 30, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change from Baseline in Visual Analogue Scale (VAS)",
                              "Change from Baseline in Western Ontario and McMaster Universities Osteoarthritis Index Score (WOMAC)",
                              "Change from Baseline in knee function change and improvement (IKDC)",
                              "Change from Baseline in Knee Injury and Osteoarthritis Outcome Score (KOOS)"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "VAS score",
                              "WOMAC score",
                              "IKDC score",
                              "KOOS score"
                        ],
                        "NCTId": [
                              "NCT04520945"
                        ]
                  },
                  {
                        "Rank": 39,
                        "OverallOfficialName": [
                              "Piotr Musia\u0142ek, MD, PhD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 27, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Left ventricle ejection fraction (LVEF) increase, assessed by SPECT at 6M FU vs. during index (baseline) imaging - comparison between two groups (active vs placebo therapy)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Left ventricle ejection fraction (LVEF) increase"
                        ],
                        "NCTId": [
                              "NCT03418233"
                        ]
                  },
                  {
                        "Rank": 40,
                        "OverallOfficialName": [
                              "Mariusz Trystu\u0142a, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Active, not recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2",
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 31, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change in pain-free walking distance (6M FU vs index evaluation) between two groups (active vs placebo therapy)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in pain-free walking distance"
                        ],
                        "NCTId": [
                              "NCT03423732"
                        ]
                  }
            ]
      }
}